Adult stem cell companies are pivoting their businesses to commercialize exosomes as therapeutics.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Biodistribution of Exosomes and Engineering Strategies for Targeted Delivery of Therapeutic Exosomes
Tissue Engineering and Regenerative Medicine Open Access 14 July 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zipkin, M. Exosome redux. Nat Biotechnol 37, 1395–1400 (2019). https://doi.org/10.1038/s41587-019-0326-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0326-5
This article is cited by
-
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment
BioDrugs (2022)
-
Extracellular vesicles as a next-generation drug delivery platform
Nature Nanotechnology (2021)
-
Taking the Temperature on Machine Perfusion
Current Transplantation Reports (2021)
-
Therapeutic Applications of Stem Cells and Extracellular Vesicles in Emergency Care: Futuristic Perspectives
Stem Cell Reviews and Reports (2021)
-
Strategies to Enhance Extracellular Vesicle Production
Tissue Engineering and Regenerative Medicine (2021)